A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias
Por:
Pérez-Amill, L, Armand-Ugón, M, Val-Casals, M, Martín-Herreros, B, Alamo, JR, Peña, S, Frigola, G, Altuna, A, Santos, C, Guijarro, F, Minguela, A, Bataller, A, Casanovas-Albertí, B, Uribe-Herranz, M, Navarro, I, Guerreiro, M, Sánchez-Martínez, D, Tirado, N, Velasco-Hernandez, T, Menéndez, P, Martínez, A, Rovira, M, Colomer, D, González-Navarro, EA, Esteve, J, Urbano-Ispizua, A, Montesinos, P, Delgado, J, Juan, ME and Klein-González, N
Publicada:
1 oct 2025
Ahead of Print:
1 ago 2025
Resumen:
Despite the remarkable clinical successes of chimeric antigen receptor (CAR) T-cell therapies in treating B-cell malignancies and multiple myeloma, similar outcomes have not been achieved in other indications. For patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), treatment options are limited, yet CART-cell therapies offer significant potential to address this unmet need. Here, we introduce a first-in-class CART-cell therapy targeting CD84, a novel antigen, for the treatment of R/R AML and T-ALL. CD84 is highly expressed on leukemic blasts, with limited expression on hematopoietic stem progenitor cells (HSPC), and is largely absent in healthy human tissues. Our second-generation CARTs targeting CD84 (CART84) demonstrate potent cytotoxicity against AML and T-ALL cells both in vitro and in vivo in patient-derived xenograft (PDX) models. Furthermore, CART84 eliminated primary leukemic blasts while exhibiting low cytotoxicity against CD34+ HSPC in vitro and in humanized mouse models in vivo, suggesting a low risk of myelotoxicity. These results support CD84 as a promising target for AML and T-ALL and provide the foundation for our upcoming first-in-human phase I/II clinical trial using CD84-directed CAR T cell therapy for patients with R/R AML and T-ALL (EudraCT 2024-519966-31-00).
Filiaciones:
Pérez-Amill, L:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Gyala Therapeut SL, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Armand-Ugón, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Gyala Therapeut SL, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Val-Casals, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Martín-Herreros, B:
Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain
Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain
Alamo, JR:
Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain
Peña, S:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Gyala Therapeut SL, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Frigola, G:
Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain
Altuna, A:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Santos, C:
Gyala Therapeut SL, Barcelona, Spain
Guijarro, F:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain
Minguela, A:
Clin Univ Hosp Virgen Arrixaca HCUVA, Immunol Serv, Murcia, Spain
Biomed Res Inst Murcia Pascual Parrilla IMIB PP, Murcia, Spain
Bataller, A:
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain
Casanovas-Albertí, B:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Uribe-Herranz, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Navarro, I:
Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain
Guerreiro, M:
Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain
Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain
Sánchez-Martínez, D:
Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain
Aragon Hlth Res Inst, Aragon ID Fdn, Zaragoza, Spain
Tirado, N:
Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain
Velasco-Hernandez, T:
Univ Barcelona, Sch Med, Barcelona, Spain
Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain
:
Univ Barcelona, Sch Med, Barcelona, Spain
Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Pediat Canc Ctr Barcelona PCCB SJD, Inst Recerca Hosp St Joan De Deu, Barcelona, Spain
Martínez, A:
Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain
Rovira, M:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
Colomer, D:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
González-Navarro, EA:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Esteve, J:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
Urbano-Ispizua, A:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
Montesinos, P:
Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain
Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Delgado, J:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Juan, ME:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Univ Barcelona, Sch Med, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Klein-González, N:
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain
Gyala Therapeut SL, Barcelona, Spain
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Green Submitted, hybrid
|